Clinical and genomic data integration in support of biomedical research and clinical practice
DOI:
https://doi.org/10.14806/ej.18.B.595Abstract
Eric Neumann is a graduate from MIT and holds a PhD in neurobiology, developmental genetics, and pharmacology from Case Western Reserve University. He is a recognized expert in semantic information, and has worked on many information initiatives for the pharmaceutical and life sciences, including the W3C Semantic Web Healthcare and Life Science Interest Group (HCLSIG).
Eric Neumann was the Global Head of Knowledge Management for Scientific and Medical Affairs within Sanofi-Aventis and the VP of Informatics at BG Medicine. He founded Genstruct (now Sleventa) and has also worked at Bolt, Beranek, and Newman (now BBN Technologies - Raytheon) on several advanced scientific computation projects over the span of several years.
He is Founder and CTO of PanGenX, a personalized medicine company, whose mission is to optimize therapeutic care by facilitating the discovery and application of medical knowledge towards patient segmentation.
Starting from the current definition of pharmacogeomics, in his talk Eric Neumann will show how it drives the personalized medicine vision, and will discuss what new forms of clinical and genomic information will be required for making clinical decision in personalized medicine.
He will illustrate some available public data sources, showing what they still lack and the value of deep focus curation. He will contrast data vs. "Actionable Knowledge" and discuss how leveraging semantically linked data to help progress personalized medicine. He will also address large-scale analytics and argue about who will benefit from linked knowledge.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).